I agree with your remarks. However, in case Inovio has already surpass this technology, it reminds us that this science is radical, and as Heraclitus said, "panta rhei", everything flows, sometimes in favor of Inovio...
Published on December 17, 2013 at 12:54 AM
"Testing the efficacy of vaccines in clinical trials takes years, even decades. Yet challenging infections like HIV, malaria and dengue are striking today. To speed up vaccine testing, scientists at the Emory Vaccine Center have established a goal of creating a "vaccine gene chip."
This device could read the activity of all the genes in the genome in white blood cells within a few days of administration of a test vaccine. Reading such "molecular signatures" would rapidly help predict the ability of that vaccine to stimulate the immune system and protect against disease.
Now scientists led by Bali Pulendran, PhD have taken an important step toward making such a chip, by comparing the molecular signatures induced by five very different vaccines in the immune systems of human volunteers. The results are published online in Nature Immunology."
HIV, Malaria and Dengue virus are all in our pipeline, this is good news for Inovio.
In case of INO, never. 100%. Inovio in 2014 will follow 2013 pattern. A peer reviewed article about HPV Phase II trial, means a successful trial, like Inovio did with HIV trial in 2013 which was delayed also.
Plus, discussions with other pharmas, Dr. Kim referred to them in spring 2013, Roche deal came in September. If it will take a few months this time too, then a new partnership will come before the HPV results...
Good Luck to you too Dragan, I wish you to find another stock like INO in the next 3 years. I wish the same for myself.
Still there is a difference. Roche sees now from inside how Inovio's team can complete a study in a few weeks and publish a peer reviewed paper. Roche is now the most possible. ..next partner of Inovio for other vaccines.
With a HIV or HPV new partnership the potential revenues from Roche can be over $1 billion.
Cancer Gene Therapy advance online publication, 6 December 2013; doi:10.1038/cgt.2013.65.
Roche and Inovio Pharmaceuticals partner on Inovio's prostate cancer and hepatitis B immunotherapy products in September, I think this study about hep B will show to Roche how effective Inovio's scientists and their partners are.
There are well over a quarter of a billion chronic hepatitis B virus (HBV) carriers across the globe. Most carriers are at high risk for development of liver cirrhosis and subsequent progression to hepatocellular carcinoma. It is therefore imperative to develop new approaches for immunotherapy against this infection. Antibodies and cytotoxic T cells to different HBV antigens are believed to be important for reducing viral load and clearing HBV-infected cells from the liver. Some of the major challenges facing current vaccine candidates have been their inability to induce both humoral and cellular immunity to multiple antigenic targets and the induction of potent immune responses against the major genotypes of HBV. In this study, highly optimized synthetic DNA plasmids against the HBV consensus core (HBc) and surface (HBs) antigens genotypes A and C were developed and evaluated for their immune potential. These plasmids, which encode the most prevalent genotypes of the virus, were observed to individually induce binding antibodies to HBs antigens and drove robust cell-mediated immunity in animal models. Similar responses to both HBc and HBs antigens were observed when mice and non-human primates were inoculated with the HBc-HBs cocktails. In addition to the cytotoxic T lymphocyte activities exhibited by the immunized mice, the vaccine-induced responses were broadly distributed across multiple antigenic epitopes. These elements are believed to be important to develop an effective therapeutic vaccine. These data support further evaluation of multivalent synthetic plasmids as therapeutic HBV vaccines.
DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses in mice and Rhesus macaques.
Obeng-Adjei N, Hutnick NA, Yan J, Chu JS, Myles DJ, Morrow MP, Sardesai NY, Weiner DB.
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
"Another big quarter for human papillomavirus (HPV) vaccine Gardasil means the vaccine unit is up 15% over the first 9 months of the year. Gardasil achieved year-over-year growth of 15% in the third quarter, despite Japan's ongoing investigation into the safety of the vaccine causing international sales to fall. Merck is providing Japan with a "vast amount persuasive safety and efficacy data" in a bid to regain the government's recommendation, global human health president Adam Schechter said, but for now strong sales in the U.S. are offsetting problems overseas.
The U.S. public sector bought $60 million of Gardasil in the quarter--as well as $30 million of rotavirus vaccine RotaTeq--and this contributed to a 30% jump in sales of the HPV jab in Merck's home market. U.S. sales were also buoyed by increased uptake in boys. The next step is to win approval for V503, Merck's 9-valent HPV vaccine. Merck provided an update on V503 to the Advisory Committee on Immunization Practices, revealing it met its primary endpoints in a Phase III trial. The positive data means Merck is still on track to submit a biologics license application to the FDA by the end of the year."
Subscribe at FierceVaccines
Firstly you should read the data from Inovio's site and then read the news to be informed about the facts.
If you prefer to depend your investing decisions to what others "feel" about Inovio, then it's better for you to sell, IMHO.
I read it in Greek media thru internet, drug addict do that for the monthly sick pay of 700 euros...
Indeed, Inovio is a little frugal to provide data on its biol-terror viruses programs.
The, mostly third party funded, programs in Inovio's pipeline show that they don't pick casually viruses to study.
Therefore I believe in the next months or even sooner we will have news about MERS program and who has interest on it.
Inovio is collaborating with Dr. Connie Schmaljohn, Chief Scientist at the USAMRIID already. They are working on Ebola and Lassa viruses. These are arenaviruses which are considered as biol-terror viruses, like the coronaviruses.
Yes it's almost seven months. Ten studies in seven months, I think the number is quite impressive for the size of Inovio.
NIAID and Inovio:
"In the first half of 2014, in collaboration with HVTN, Inovio intends to launch a phase 1 clinical study of PENNVAX-GP, our primary preventive and therapeutic HIV vaccine. Funding for this study is provided for under Inovio's $25-plus million NIAID development contract."
"April 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has been selected to receive a $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID)"
Release Date: September 20, 2013
NIAID is issuing this Notice to highlight its interest in receiving grant applications focused on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) research. Areas of high priority include, but are not limited to, the following:
Basic research to understand MERS-CoV infection, replication, pathogenesis, and transmission.
Studies on the evolution and emergence of MERS CoV viruses including the identification of factors that affect MERS CoV host-range and virulence;
Virologic and serologic surveillance studies of the distribution and natural history of MERS-CoV viruses in animal populations and in humans at the human/animal interface, with particular emphasis on hosts(s) reservoirs and understanding cross-species transmission events;
The development of sensitive, specific, and rapid clinical diagnostic tests for MERS CoV;
Development of drugs against MERS CoV and broad spectrum therapeutics against multiple coronavirus strains, including structure/function studies of MERS CoV proteins with the goal of identifying new therapeutic targets; Evaluation of the immune response to infection and/or vaccination including cell-mediated and innate immunity
The development of novel MERS CoV vaccines and vaccination strategies based on evolving knowledge of host/pathogen interactions and identification of relevant biomarkers.
Thank you catchinem_all for bringing the opportunity for this conversation.
I think everyone should read bamapride57, lawdawwgg, perugeorges and others messages below. They give a good example of what could happen until the HPV results, like in the first semester of 2013, when while we expected the HIV study other catalysts drove the stock significantly higher.